Skip to main content
. 2021 Mar 8;10(5):1125. doi: 10.3390/jcm10051125

Figure 2.

Figure 2

Treatment options overview for advanced classical Hodgkin lymphoma (cHL). The figure displays treatment approaches reviewed in clinical trials. Either escalating treatment to improve progression-free survival rates (PFS) by PET-guided switching to eBEACOPP or by addition of new drugs (BV) or de-escalation of efficient but toxic treatment approaches guided by PET/CT or including new targeted drugs.